A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Phase of Trial: Phase II
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs Tenofovir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors CONRAD
- 31 May 2019 According to an Orion Biotechnology Canada Media release, results are presented at the International Journal of STD & AIDS.
- 25 Feb 2016 Results presented at the 23rd Conference on Retroviruses and Opportunistic Infections
- 04 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.